Detalhe da pesquisa
1.
Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
J Hematol Oncol
; 15(1): 42, 2022 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35410313
2.
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
Cancer Cell
; 27(4): 473-88, 2015 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25873171
3.
A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo.
Cancer Cell
; 23(4): 502-15, 2013 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23597564